ALLOGENE THERAPEUTICS
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
ALLOGENE THERAPEUTICS
Industry:
Biotechnology Health Diagnostics Oncology Pharmaceutical
Founded:
2017-01-01
Status:
Active
Contact:
650-457-2700
Email Addresses:
[email protected]
Total Funding:
1.01 B USD
Technology used in webpage:
Domain Not Resolving Google Maps IPv6 Microsoft COVID-19 Gravity Forms Akamai Hosted Comcast
Similar Organizations
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Geron
Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel,
Interius BioTherapeutics
Interius BioTherapeutics is a biopharmaceutical company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.
Mirvie
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health.
Proscia
Proscia develops a pathology platform to assist routine pathology operations, enhance cancer diagnosis, and improve patient outcomes.
Vittoria Biotherapeutics
Vittoria Biotherapeutics is a gene-edited cell therapeutics company.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Franklin Templeton
Franklin Templeton investment in Convertible Note - Allogene Therapeutics
Jennison Associates
Jennison Associates investment in Convertible Note - Allogene Therapeutics
venBio Select Advisor
venBio Select Advisor investment in Convertible Note - Allogene Therapeutics
Fidelity
Fidelity investment in Convertible Note - Allogene Therapeutics
Deerfield Capital Management
Deerfield Capital Management investment in Convertible Note - Allogene Therapeutics
Surveyor Capital
Surveyor Capital investment in Convertible Note - Allogene Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Convertible Note - Allogene Therapeutics
T. Rowe Price
T. Rowe Price investment in Convertible Note - Allogene Therapeutics
Cowen Investment Management
Cowen Investment Management investment in Convertible Note - Allogene Therapeutics
TPG
TPG investment in Series A - Allogene Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-07-27 | Antion Biosciences | Allogene Therapeutics investment in Corporate Round - Antion Biosciences | 4 M USD |
| 2022-01-11 | Antion Biosciences | Allogene Therapeutics investment in Corporate Round - Antion Biosciences | 3 M USD |
| 2021-02-10 | Notch Therapeutics | Allogene Therapeutics investment in Series A - Notch Therapeutics | 85 M USD |
| 2019-11-06 | Notch Therapeutics | Allogene Therapeutics investment in Corporate Round - Notch Therapeutics | 1000 K USD |
Key Employee Changes
More informations about "Allogene Therapeutics"
Allogene Therapeutics - LinkedIn
Allogene Therapeutics | 72,437 followers on LinkedIn. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of …See details»
Allogene Therapeutics - The Org
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) …See details»
Allogene Therapeutics - Crunchbase Company Profile & Funding
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.See details»
Company: Allogene Therapeutics - crisprmedicinenews.com
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen …See details»
Allogene Therapeutics, Inc. (ALLO) - Yahoo Finance
See the company profile for Allogene Therapeutics, Inc. (ALLO) including business summary, industry/sector information, number of employees, business summary, corporate governance, key …See details»
Allogene Therapeutics - 2025 Company Profile & Team - Tracxn
Aug 3, 2025 Allogene Therapeutics is a public company based in San Francisco (United States), founded in 2018 by David Chang and Arie Belldegrun. It operates as a Developer of chimeric …See details»
Allogene Therapeutics (ALLO) Company Profile & Description
Oct 11, 2018 Company profile for Allogene Therapeutics, Inc. (ALLO) stock, with a description, list of executives, contact details and other key facts.See details»
Allogene Therapeutics Inc: Overview - GlobalData
Up-to-date Allogene Therapeutics Inc company overview including funding information, company profile, key statistics, peer comparison and more.See details»
About Us - Allogene
REDEFINING THEFUTURE OF CAR T LEARN ABOUT OUR SCIENCE Allogene Therapeutics is a clinical-stage …See details»
Allogene Therapeutics (ALLO): The Future of Off-the-Shelf CAR T …
Looking toward 2030, Allogene Therapeutics represents one of the most compelling asymmetric opportunities in biotech. With its healthy cash reserves, intelligent fiscal discipline, and pipeline …See details»
Investor Relations | Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR …See details»
Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
2 days ago Allogene Therapeutics discusses Q2 2025 milestones and pipeline updates, including notable progress in CAR T-cell therapy for cancer and autoimmune diseases.See details»
Allogene Therapeutics, Inc. (ALLO) - Yahoo Finance
Find the latest Allogene Therapeutics, Inc. (ALLO) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Allogene Therapeutics Reports Second Quarter 2025 Financial …
2 days ago About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic …See details»
Allogene Therapeutics’ SWOT analysis: stock faces challenges amid ...
2 days ago Market Position and Competition Allogene operates in the highly competitive field of CAR T-cell therapies, where it faces challenges from both established players and emerging …See details»
Allogene Therapeutics Reports Second Quarter 2025 ... - Morningstar
3 days ago Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell …See details»
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights ...
2 days ago Allogene Therapeutics Inc (ALLO) showcases significant progress in clinical trials and maintains a strong cash position, despite facing safety concerns and financial hurdles.See details»
Allogene Therapeutics: Important Catalysts Guided For Early ...
1 day ago Discover why Allogene Therapeutics' diverse cell therapy pipeline and solid financials make it a top buy.See details»
News Center - Allogene
NEWS CENTER LEARN ABOUT AlloCAR T™ PRODUCTS LATEST PRESS RELEASES Apr 26, 2024 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative …See details»
Allogene Therapeutics Reports Second Quarter 2025 Financial …
2 days ago SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the …See details»